BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.060
-0.030 (-2.75%)
At close: Apr 28, 2026, 4:00 PM EDT
1.060
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:39 PM EDT
BioXcel Therapeutics Employees
BioXcel Therapeutics had 29 employees as of December 31, 2025. The number of employees decreased by 8 or -21.62% compared to the previous year.
Employees
29
Change (1Y)
-8
Growth (1Y)
-21.62%
Revenue / Employee
$22,138
Profits / Employee
-$2,410,241
Market Cap
28.70M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| China Pharma Holdings | 215 |
| Rockwell Medical | 157 |
| Cumberland Pharmaceuticals | 93 |
| Aytu BioPharma | 83 |
| Talphera | 12 |
| Incannex Healthcare | 12 |
BTAI News
- 5 days ago - BioXcel Therapeutics Transcript: Investor update - Transcripts
- 11 days ago - BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - GlobeNewsWire
- 18 days ago - Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 20 days ago - BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - GlobeNewsWire
- 27 days ago - BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - GlobeNewsWire
- 4 weeks ago - BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - GlobeNewsWire